Managing toxicities of BCMA_targeting Bispecfics

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.

EP: 1.Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

EP: 2.MonumenTAL-1: Long Term Follow up Efficacy

EP: 3.MonumenTAL-1: Safety and AEs

EP: 4.Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

EP: 5.Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS

Now Viewing

EP: 6.Managing toxicities of BCMA_targeting Bispecfics

EP: 7.Management of Oral Toxcities associated with GPRC5D Bispecifics Nail

EP: 8.Management of Skin and Nail AEs: Advice to Patients and Caregivers

EP: 9.Prophylactic Strategies and Advice for Managing AEs in Bispecific Therapies

EP: 10.Unmet Needs and Future Perspectives on the treatment of R/R MM

Video content above is prompted by the following:

What are some other toxicities observed with B-cell maturation antigen–targeting bispecifics? How are they managed in your practice?

• Infections, neurotoxicity, hematological toxicities

Recent Videos